Non-prescribing of clozapine for outpatients with schizophrenia in real-world settings: The clinicians' perspectives.

Clozapine is the gold standard for treating treatment-resistant schizophrenia although continuously underutilized. Previous surveys of clinicians have found that some of the most frequently cited barriers to clozapine prescribing are related to the blood-monitoring requirements. However, these surveys tend to explore general perspectives and may not reflect the true impact of different barriers in real-world outpatient settings.

[Not Available].

ECT is generally regarded as a safe and efficient treatment. In this case report, a 76-year-old female patient did not wake up as expected after ECT. The patient was transferred to the emergency department, and a CT-scan showed an intracerebral haemorrhage.

Patients' and psychiatrists' perspectives on clozapine treatment-a scoping review protocol.

Introduction: The atypical antipsychotic clozapine has shown superior efficacy compared with other antipsychotics and is the gold standard for treating otherwise treatment resistant schizophrenia. However, multiple studies have found that clozapine is underutilised in most parts of the world. A few reviews of literature addressing barriers to clozapine prescribing have been conducted.

Clozapine-associated neutropenia following augmentation with sodium valproate.

Clozapine is gold standard for the management of treatment-resistant schizophrenia. It can offer life-changing symptom reduction where other antipsychotics have failed, and for these patients, treatment with clozapine should be maintained, if in any possible way. However, treatment with clozapine comes with a risk of developing potentially fatal adverse reactions, for example, severe neutropenia or agranulocytosis, in which case, treatment must be discontinued.